ALSO NOTED: Teva's Accupril gets FDA OK; Elder Pharmaceuticals buys Biomeda;
> Teva has nabbed an OK from the FDA for its generic form of Accupril, Pfizer's high blood pressure remedy. Total U.S. sales of the drug--branded and generic forms--amounted to $150 million for the 12 months ended June 30. Release
> Indian drug maker Elder Pharmaceuticals has agreed to buy Bulgaria's Biomeda Group for €10 million in cash. It's Elder's second acquisition in two months; the company hopes to use Biomeda as leverage for more European product launches. Report
> Medical laser-maker Candela got a new indication from the FDA for its Serenity device, used to reduce pain during pulsed-light and laser treatments. Report
And Finally... Low-dose products for menopause treatment have flooded the market with since the Women's Health Initiative found that hormone therapy could be harmful. But there's no research proving low doses are safer than traditional products. Article
Comments
Post new comment
Paid Research Reports
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
- The Emerging Role of Postmarketing Clinical Research: Regulatory issues, strategic drivers and overall trends

